



Martinez-Gonzalez, LJ, Sanchez-Conde, V, Gonzalez-Cabezuelo, JM. et al. Identification of miRNAs as viable aggressiveness biomarkers for prostate cancer.

Supplementary Figure S1. Selection of candidate miRNA normalizer assay.




Footnote Figure S1. Cycle threshold (Ct) values of different tested endogenous controls (RNU6, GAPDH, and miR-130b) in tissue samples. After studying different normalization methods using these previous selected endogenous controls and all the ten miRNAs of present work, we concluded that normalization using RNU6B as control is the best option. In the graph it can be seen that RNU6B normalizer shows less variability and earlier Ct values than miR-130b

Supplementary Figure S2. Volcano Plot comparing non-tumoral samples (G0) with tumoral samples Gleason score ≤ 7 (G1).



Footnote Figure S2. Volcano plot represents miRNAs dispersion according to their expression patterns; using logFC (X axis) versus statistical significance FDR (Y axis). In blue, they are represented those miRNAs that are not differentially expressed contrasting with DE analysis; which are represented in red. As nearer to the left side, miRNAs are under-expressed contrasting with those closer to the right side; which are over-expressed. Moreover, those miRNAs which are on the upper part of the Y axis have a stronger statistical significance. Most interesting miRNAs for present work are identified surrounded by a circle.

Supplementary Figure S3. Volcano Plot comparing non-tumoral samples (G0) with tumoral samples Gleason score > 7 (G2).




Footnote Figure S3. Volcano plot represents miRNAs dispersion according to their expression patterns; using logFC (X axis) versus statistical significance FDR (Y axis). In blue, they are represented those miRNAs that are not differentially expressed contrasting with DE analysis; which are represented in red. As nearer to the left side, miRNAs are under-expressed contrasting with those closer to the right side; which are over-expressed. Moreover, those miRNAs which are on the upper part of the Y axis have a stronger statistical significance. Most interesting miRNAs for present work are identified surrounded by a circle.


Supplementary Figure S4. Expression patterns of miRNAs (141, 375 and 130b).

a) Representing Gleason scores ≤ 7 versus Gleason scores > 7 ; b) Representing T-Stage T1-T2 versus T3-T4.


a)



b)




Supplementary Figure S5. Expression patterns of miRNAs (141, 375 and 130b) according to PSA values ranged in $> 4 < 10$ ng/ml, $> 10 < 20$ ng/ml and > 20 ng/ml.




Martinez-Gonzalez, LJ, Sanchez-Conde, V, Gonzalez-Cabezuelo, JM. et al. Identification of miRNAs as viable aggressiveness biomarkers for prostate cancer.

Supplementary Figure S6. miRNA 93-5p expression patterns in tissue and plasma using ΔCT normalisation with RNU6B.



Footnote Figure S6. At the left we could see a significant over-expression pattern in miRNA 93-5p (<0.0001). At the right side, we could see as in plasma there is also an over-expression pattern, but with not significant values due to the sample size ($n=60$).

Supplementary Figure S7. JAK-STAT signalling pathway.



Martinez-Gonzalez, LJ, Sanchez-Conde, V, Gonzalez-Cabezuelo, JM. et al. Identification of miRNAs as viable aggressiveness biomarkers for prostate cancer.

Supplementary Table S1. Values obtained for selection of the best housekeeping in tissue samples.

Gene	Ct	SD	CV
GAPDH	27.057	4.211	0.156
RNU6B	29.466	1.751	0.059
miR-130b	31.876	2.597	0.081

Footnote Table S1. SD (Standard Variation); CV (Variation coefficient); Ct (Cycle threshold).

Martinez-Gonzalez, LJ, Sanchez-Conde, V, Gonzalez-Cabezuelo, JM. et al. Identification of miRNAs as viable aggressiveness biomarkers for prostate cancer.

Supplementary Table S2. Reported data of housekeepings according NormFinder and BestKeeper tools.

Gene	<i>NormFinder</i>		<i>BestKeeper</i>		
	Stability value	Standard Error	Range	Deviation	Range
RNU6B	0.734	0.431	1	1.15	1
miR-130b	1.418	0.263	2	1.22	2
GAPDH	2.670	0.286	3	3.29	3

Martinez-Gonzalez, LJ, Sanchez-Conde, V, Gonzalez-Cabezuelo, JM. et al. Identification of miRNAs as viable aggressiveness biomarkers for prostate cancer.

Supplementary Table S3. Details of the probes.

Assay Name	Assay ID	Mature miRNA Sequence
miR-592	479075 mir	UUGUGUCAAAU AUGCGAUGAUGU
miR-23c	478783 mir	AUCACAUUGCAGUGAUUACCC
miR-93-5p	478210 mir	CAAAGUGCUGUUUCGUGCAGGUAG
miR-210-3p	477970 mir	CUGUGCGUGUGACAGCGGCUGA
miR-221-3p	477981 mir	AGCUACAUUGUCUGCUGGGUUUC
miR-141-5p	478712 mir	CAUCUCCAGUACAGUGUUGGA
miR-375-3p	478074 mir	UUUGUUCGUUCGGCUCGCGUGA
miR-130b-3p	477840 mir	CAGUGCAAUGAUGAAAGGGCAU

Martinez-Gonzalez, LJ, Sanchez-Conde, V, Gonzalez-Cabezuelo, JM. et al. Identification of miRNAs as viable aggressiveness biomarkers for prostate cancer.

Supplementary Table S4. Candidate miRNAs for diagnostic biomarkers of PC (G0 vs G1)

miRNA	logFC	F	PValue	FDR
miR-891a-5p	-4.68071	524.75245	2.11794×10^{-81}	1.12463×10^{-78}
miR-1251-5p	-2.98162	222.13762	2.95098×10^{-42}	7.83485×10^{-40}
miR-23c	-2.79229	209.27812	2.93773×10^{-40}	5.19979×10^{-38}
miR-93-5p	1.60176	191.57714	1.89048×10^{-37}	2.50961×10^{-35}
miR-323b-3p	-2.44272	178.19999	2.79127×10^{-35}	2.96433×10^{-33}
miR-27b-3p	-0.97078	177.21132	4.05297×10^{-35}	3.58688×10^{-33}
miR-652-3p	-1.23890	175.95381	6.51806×10^{-35}	4.94442×10^{-33}
miR-204-5p	-1.80311	171.46500	3.5789×10^{-34}	2.37549×10^{-32}
miR-200c-3p	1.56315	160.82584	2.11939×10^{-32}	1.25044×10^{-30}
miR-889-3p	-1.21975	149.14740	2.0145×10^{-30}	1.06973×10^{-28}
miR-92a-3p	1.13074	141.95792	3.46116×10^{-29}	1.67083×10^{-27}
miR-17-5p	1.42355	138.77909	1.22922×10^{-28}	5.43928×10^{-27}
miR-148a-3p	1.36335	138.46089	1.39596×10^{-28}	5.70194×10^{-27}
miR-96-5p	1.79812	135.53316	4.51269×10^{-28}	1.71162×10^{-26}
miR-99b-3p	-0.97138	134.34153	7.28612×10^{-28}	2.57929×10^{-26}
miR-23b-3p	-0.86368	133.46958	1.03511×10^{-27}	3.43525×10^{-26}
miR-221-3p	-1.30280	131.63828	2.16729×10^{-27}	6.76958×10^{-26}
miR-20a-5p	1.61505	131.04489	2.75488×10^{-27}	8.12691×10^{-26}
miR-375	1.86559	126.97730	1.43515×10^{-26}	4.01086×10^{-25}
miR-145-3p	-1.02683	124.98426	3.23434×10^{-26}	8.58716×10^{-25}
miR-141-3p	1.35452	81.02212	3.91529×10^{-18}	4.33129×10^{-17}
miR-141-5p	0.81289	62.63751	1.44426×10^{-14}	1.14463×10^{-13}
miR-130b-5p	0.97376	43.12139	1.22171×10^{-10}	6.17839×10^{-10}
miR-130b-3p	0.78417	40.54807	4.13977×10^{-10}	1.91149×10^{-09}
miR-592	1.25212	13.84071	0.000220054	0.000444291

Footnote Table S4. Abbreviations: DE (Differential expression); logFC (logarithmic fold change); F (Quasi-likelihood F-statistic for the GLM (Quasi Likelihood F-test)); FDR (False Discovery Rate). Here comparisons were performed including tissue samples comparing non-tumoral area (G0; n = 51) with tumoral tissue area above Gleason ≤7 (G1; n = 285).

Martinez-Gonzalez, LJ, Sanchez-Conde, V, Gonzalez-Cabezuelo, JM. et al. Identification of miRNAs as viable aggressiveness biomarkers for prostate cancer.

Supplementary Table S5. Candidate miRNAs for diagnostic biomarkers of PC (G0 vs G2).

miRNA	logFC	F	PValue	FDR
miR-891a-5p	-5.36828	525.99579	1.54729 × 10 ⁻⁸¹	8.21611 × 10 ⁻⁷⁹
miR-23c	-3.69722	298.41920	1.91778 × 10⁻⁵³	5.09171 × 10⁻⁵¹
miR-93-5p	1.95193	260.37810	5.31929 × 10⁻⁴⁸	9.41515 × 10⁻⁴⁶
miR-145-3p	-1.50865	256.42740	2.02380 × 10 ⁻⁴⁷	2.68660 × 10 ⁻⁴⁵
miR-221-3p	-1.84835	249.41856	2.20268 × 10⁻⁴⁶	2.33925 × 10⁻⁴⁴
miR-222-3p	-1.55122	200.09936	8.23706 × 10 ⁻³⁹	7.28980 × 10 ⁻³⁷
miR-23b-3p	-1.08182	195.40754	4.60195 × 10 ⁻³⁸	3.49091 × 10 ⁻³⁶
miR-204-5p	-2.01057	190.37724	2.94762 × 10 ⁻³⁷	1.95648 × 10 ⁻³⁵
miR-27b-3p	-1.03189	182.91807	4.74251 × 10 ⁻³⁶	2.79808 × 10 ⁻³⁴
miR-378d	-2.26930	181.64211	7.65033 × 10 ⁻³⁶	4.06232 × 10 ⁻³⁴
miR-96-5p	2.166465	180.90695	1.00810 × 10 ⁻³⁵	4.86638 × 10 ⁻³⁴
miR-133b	-2.30342	176.18918	5.96302 × 10 ⁻³⁵	2.63863 × 10 ⁻³³
miR-1251-5p	-2.86172	172.92863	2.05142 × 10 ⁻³⁴	8.37927 × 10 ⁻³³
miR-708-3p	1.587019	165.89458	3.00833 × 10 ⁻³³	1.14101 × 10 ⁻³¹
miR-136-3p	-1.71603	165.60550	3.36134 × 10 ⁻³³	1.18991 × 10 ⁻³¹
miR-200c-3p	1.618519	164.66236	4.82911 × 10 ⁻³³	1.60266 × 10 ⁻³¹
miR-17-5p	1.588999	162.21678	1.23853 × 10 ⁻³²	3.86859 × 10 ⁻³¹
miR-425-5p	1.708293	160.52788	2.37820 × 10 ⁻³²	7.01570 × 10 ⁻³¹
miR-375	1.988737	136.97024	2.53528 × 10⁻²⁸	4.98606 × 10⁻²⁷
miR-141-3p	1.522050	95.83539	6.34610 × 10⁻²¹	5.91189 × 10⁻²⁰
miR-592	3.252722	81.48417	3.19623 × 10⁻¹⁸	2.49588 × 10⁻¹⁷
miR-210-3p	2.024351	53.96053	7.70099 × 10⁻¹³	3.49506 × 10⁻¹²
miR-141-5p	0.766069	53.28103	1.05448 × 10⁻¹²	4.58960 × 10⁻¹²
miR-130b-3p	0.777535	37.92062	1.44995 × 10⁻⁰⁹	4.78216 × 10⁻⁰⁹
miR-130b-5p	0.793059	27.76311	1.99271 × 10⁻⁰⁷	5.03871 × 10⁻⁰⁷

Footnote Table S5. Abbreviations: DE (Differential expression); logFC (logarithmic fold change); F (Quasi-likelihood F-statistic for the GLM (Quasi Likelihood F-test)); FDR (False Discovery Rate). Here comparisons were performed comparing non-tumoral area (G0; n = 51) with tumoral tissue area above Gleason >7 (G2; n = 195).

Supplementary Table S6. Comparisons values between TCGA and qPCR analysis developed in biopsy and plasmas from peripheral blood.

	TCGA		PVal	Biopsy	PVal	Plasmas		PVal
miR-210-3p	G0vsG1	Over-expressed (G1)	-	G0vsG1	Over-expressed (G1)	<0.0001	G1vsG2	Under-expressed (G2)
	G0vsG2	Over-expressed (G2)	7.700×10^{-13}	G0vsG2	Over-expressed (G2)	1.852×10^{-10}		
	G1vsG2	Over-expressed (G2)	1.894×10^{-23}	G1vsG2	Over-expressed (G2)	0.001		
miR-221-3p	G0vsG1	Under-expressed (G1)	2.167×10^{-27}	G0vsG1	Over-expressed (G1)	<0.0001	G1vsG2	Over-expressed (G2)
	G0vsG2	Under-expressed (G2)	2.202×10^{-46}	G0vsG2	Over-expressed (G2)	<0.0001		
	G1vsG2	Under-expressed (G2)	-	G1vsG2	Over-expressed (G2)	-		
miR-23c	G0vsG1	Under-expressed (G1)	2.937×10^{-40}	G0vsG1	Over-expressed (G1)	1.065×10^{-05}	G1vsG2	Over-expressed (G2)
	G0vsG2	Under-expressed (G2)	1.917×10^{-53}	G0vsG2	Over-expressed (G2)	4.297×10^{-07}		
	G1vsG2	Under-expressed (G2)	1.609×10^{-07}	G1vsG2	Under-expressed (G1)	-		
miR-93-5p	G0vsG1	Over-expressed (G1)	1.890×10^{-37}	G0vsG1	Over-expressed (G1)	3.434×10^{-05}	G1vsG2	Over-expressed (G2)
	G0vsG2	Over-expressed (G2)	5.319×10^{-48}	G0vsG2	Over-expressed (G2)	2.123×10^{-11}		
	G1vsG2	Over-expressed (G2)	-	G1vsG2	Over-expressed (G2)	<0.0001		
miR-592	G0vsG1	Over-expressed (G2)	<0.0001	G0vsG1	Over-expressed (G1)	-	G1vsG2	ND
	G0vsG2	Over-expressed (G2)	3.196×10^{-18}	G0vsG2	Over-expressed (G2)	-		
	G1vsG2	Over-expressed (G2)	1.141×10^{-30}	G1vsG2	Over-expressed (G2)	-		
miR-130b-3p	G0vsG1	Over-expressed (G1)	4.139×10^{-10}	G0vsG1	NA	-	EA	EA
	G0vsG2	Over-expressed (G2)	1.449×10^{-09}		NA	-		
	G1vsG2	Over-expressed (G2)	-	G0vsG2	NA	-		
miR-130b-5p	G0vsG1	Over-expressed (G1)	1.221×10^{-10}	G1vsG2	Over-expressed (G2)	-		
	G0vsG2	Over-expressed (G2)	1.992×10^{-07}		Over-expressed (G2)	-		
	G1vsG2	Under-expressed (G2)	-		Over-expressed (G2)	-		
miR-141-3p	G0vsG1	Over-expressed (G1)	3.915×10^{-18}	G0vsG1	NA	-		
	G0vsG2	Over-expressed (G2)	6.346×10^{-21}		NA	-		
	G1vsG2	Over-expressed (G2)	-	G0vsG2	NA	-		
miR-141-5p	G0vsG1	Over-expressed (G1)	1.444×10^{-14}	G1vsG2	Over-expressed (G2)	-		
	G0vsG2	Over-expressed (G2)	1.054×10^{-12}		Over-expressed (G2)	-		
	G1vsG2	Under-expressed (G1)	-		Over-expressed (G2)	-		
miR-375	G0vsG1	Over-expressed (G1)	1.435×10^{-26}	G0vsG1	Over-expressed (G1)	-		
	G0vsG2	Over-expressed (G2)	2.535×10^{-28}	G0vsG2	Over-expressed (G2)	-		
	G1vsG2	Over-expressed (G2)	-	G1vsG2	Over-expressed (G2)	-		

Foonote Table S6. PVal : T-test pvalue, NA: not analysed. ND: no data available. EA: Excluded from analysis after observing TCGA & Tissues results. Just those data with representative values are included (-), *except for the p-value of miR-93-5p analysis from plasmas from peripheral blood.